ERBB2 and rhabdomyosarcoma: One of the ongoing Phase I/II trials uses epidermal growth factor receptor 2 (HER2) CAR-T cells to treat advanced-stage ewing’s sarcoma (ES), osteosarcoma (OS), rhabdomyosarcoma (RMS), desmoplastic small round cell tumour (DSRC), and peripheral neuroectodermal tumour positive to the HER2 receptor after chemotherapy (NCT00902044).